A phase I trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive metastatic breast cancer

Clinical Cancer Research

Volumn 22, Issue 7, 2016, Pages 1583-1591

  Ma, Cynthia X ^a,b   Luo, Jingqin ^a   Naughton, Michael ^a,b   Ademuyiwa, Foluso ^a,b   Suresh, Rama ^a,b   Griffith, Malachi ^a,b   Griffith, Obi L ^a,b   Skidmore, Zachary L ^a   Spies, Nicholas C ^a   Ramu, Avinash ^a   Trani, Lee ^a   Pluard, Timothy ^a,b   Nagaraj, Gayathri ^a   Thomas, Shana ^a   Guo, Zhanfang ^a   Hoog, Jeremy ^a   Han, Jing ^a   Mardis, Elaine ^a,b   Lockhart, Craig ^a,b   Ellis, Matthew J ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Washington University in St Louis School of Medicine   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ANTIHISTAMINIC AGENT; ASPARTATE AMINOTRANSFERASE; BUPARLISIB; C PEPTIDE; CORTICOSTEROID; CREATININE; FULVESTRANT; GLUCOSE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; TRIACYLGLYCEROL LIPASE; AMINOPYRIDINE DERIVATIVE; ANTINEOPLASTIC AGENT; ESTRADIOL; ESTROGEN RECEPTOR; MORPHOLINE DERIVATIVE; NVP-BKM120; PHOSPHATIDYLINOSITOL 3 KINASE; PTEN PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST METASTASIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE; GENE MUTATION; GLUCOSE BLOOD LEVEL; HEART DISEASE; HUMAN; HYPERGLYCEMIA; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PANCREATITIS; PGR GENE; PHASE 1 CLINICAL TRIAL; PHOTOTOXICITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PTEN GENE; RASH; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR SUPPRESSOR GENE; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AMINOPYRIDINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; MORPHOLINES; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; POSTMENOPAUSE; PTEN PHOSPHOHYDROLASE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME;

EID: 84964318224     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1745     Document Type: Article

References (24)

1. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014;13:140-56.
2. Ellis MJ, Lin L, Crowder R, Tao Y, Hoog J, Snider J, et al. Phosphatidylinositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat 2010;119:379-90.
3. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012;486:353-60.
4. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
5. Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 2009;69:3955-62.
6. Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 2011;13:R21.
7. Ma CX, Crowder RJ, Ellis MJ. Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors. Steroids 2011;76:750-2.
8. Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Chen H, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010;120:2406-13.
9. Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther 2012;11:317-28.
10. Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, et al. ERalpha-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 2011;1:338-51.
11. Griffith OL, Griffith M, Luo J, Hundall J, Miller CA, Larson DE, et al. Prognostic effects of gene mutation in estrogen receptor-positive breast cancer [abstract]. In: Proceedings of 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2014 December 9-13; San Antonio, TX. Philadelphia (PA): AACR; 2015. Abstract nr S1-02.
12. Griffith M, Griffith OL, Smith SM, Ramu A, Callaway MB, Brummett AM, et al. Genome modeling system: a knowledge management platform for genomics. PLoS Comput Biol 2015;11:e1004274.
13. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754-60.
14. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20: 1297-303.
15. Larson DE, Harris CC, Chen K, Koboldt DC, Abbott TE, Dooling DJ, et al. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics 2012;28:311-7.
16. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012;22:568-76.
17. Saunders CT, Wong WS, Swamy S, Becq J, Murray LJ, Cheetham RK. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 2012;28:1811-7.
18. Nicol JW, Helt GA, Blanchard SG Jr, Raja A, Loraine AE. The Integrated Genome Browser: free software for distribution and exploration of genome-scale datasets. Bioinformatics 2009;25:2730-1.
19. Flicek P, Amode MR, Barrell D, Beal K, Billis K, Brent S, et al. Ensembl 2014. Nucleic Acids Res 2014;42:D749-55.
20. Xu S, Li S, Guo Z, Luo J, Ellis MJ, Ma CX. Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patientderived xenograft models. Mol Cancer Ther 2013;12:1665-75.
21. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012;30:282-90.
22. Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, et al. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2014;32:1202-9.
23. Robertson JF, Lindemann JP, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, et al. Fulvestrant 500 mgversus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. Breast Cancer Res Treat 2012;136:503-11.
24. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010;28:4594-600.